Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis

Vedolizumab is used in the treatment of inflammatory bowel disease and is generally well tolerated. We report a 20-year-old man who presented with right flank pain on a background of ulcerative colitis. He was on vedolizumab with his last dose 1 week before the onset of symptoms. Kidney function tes...

Descripción completa

Detalles Bibliográficos
Autores principales: Subhaharan, Deloshaan, Ramaswamy, Pradeep K., Francisco, Sewwandi, Ishaq, Naveed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232362/
https://www.ncbi.nlm.nih.gov/pubmed/35765681
http://dx.doi.org/10.14309/crj.0000000000000788
_version_ 1784735564242616320
author Subhaharan, Deloshaan
Ramaswamy, Pradeep K.
Francisco, Sewwandi
Ishaq, Naveed
author_facet Subhaharan, Deloshaan
Ramaswamy, Pradeep K.
Francisco, Sewwandi
Ishaq, Naveed
author_sort Subhaharan, Deloshaan
collection PubMed
description Vedolizumab is used in the treatment of inflammatory bowel disease and is generally well tolerated. We report a 20-year-old man who presented with right flank pain on a background of ulcerative colitis. He was on vedolizumab with his last dose 1 week before the onset of symptoms. Kidney function tests revealed a serum creatinine of 171 μmoL/L and a C-reactive protein of 74 mg/L. Kidney biopsy demonstrated focal acute interstitial nephritis. He was prescribed oral prednisolone and achieved complete recovery of renal function within 3 weeks. At the follow-up after 4 months, his renal function remains normal.
format Online
Article
Text
id pubmed-9232362
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-92323622022-06-27 Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis Subhaharan, Deloshaan Ramaswamy, Pradeep K. Francisco, Sewwandi Ishaq, Naveed ACG Case Rep J Case Report Vedolizumab is used in the treatment of inflammatory bowel disease and is generally well tolerated. We report a 20-year-old man who presented with right flank pain on a background of ulcerative colitis. He was on vedolizumab with his last dose 1 week before the onset of symptoms. Kidney function tests revealed a serum creatinine of 171 μmoL/L and a C-reactive protein of 74 mg/L. Kidney biopsy demonstrated focal acute interstitial nephritis. He was prescribed oral prednisolone and achieved complete recovery of renal function within 3 weeks. At the follow-up after 4 months, his renal function remains normal. Wolters Kluwer 2022-06-24 /pmc/articles/PMC9232362/ /pubmed/35765681 http://dx.doi.org/10.14309/crj.0000000000000788 Text en © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Subhaharan, Deloshaan
Ramaswamy, Pradeep K.
Francisco, Sewwandi
Ishaq, Naveed
Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
title Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
title_full Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
title_fullStr Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
title_full_unstemmed Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
title_short Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
title_sort vedolizumab-induced acute interstitial nephritis in ulcerative colitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232362/
https://www.ncbi.nlm.nih.gov/pubmed/35765681
http://dx.doi.org/10.14309/crj.0000000000000788
work_keys_str_mv AT subhaharandeloshaan vedolizumabinducedacuteinterstitialnephritisinulcerativecolitis
AT ramaswamypradeepk vedolizumabinducedacuteinterstitialnephritisinulcerativecolitis
AT franciscosewwandi vedolizumabinducedacuteinterstitialnephritisinulcerativecolitis
AT ishaqnaveed vedolizumabinducedacuteinterstitialnephritisinulcerativecolitis

Ejemplares similares